For informational purposes only — not investment advice

← Back to signals

KVUE

LONGINSIDER SELLCONGRESS BUY

KENVUE INC

Research: Finviz ↗·Perplexity ↗

🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.

Funds
3
Score
2.45
vs SPY
-5.7%
Stock return (since Q-end)
+14.0%
SPY return (since Q-end)
+19.7%
Current price
$19.20
Days to cover (short int.)
2.4d
as of 2026-06-30

News Summary

Negative

Kenvue delivered modest organic sales growth (0.7% in Q1, 1.6% in Q2) with margin expansion in Q1 but contraction in Q2 due to inflation and tariffs, while missing consensus expectations in Q2 and ending a four-quarter beat streak. The pending Kimberly-Clark acquisition (expected to close Q4 2026) dominates the investment thesis, with no forward guidance provided, and a significant headwind emerged from Trump administration warnings linking acetaminophen to autism, with Tylenol representing 12-15% of earnings.

Red flags

  • •Q2 2026 earnings miss on both top and bottom lines, ending four-quarter beat streak
  • •Adjusted gross margin compression to 60.2% from 60.9% due to inflation, tariffs, and currency headwinds
  • •Trump administration report linking acetaminophen (Tylenol) to autism risk; Tylenol represents 12-15% of earnings with stock down 20% at one point
  • •No forward guidance provided due to pending acquisition, limiting visibility
  • •UK group action lawsuit filed against Kenvue alleging talc-based products cause cancer
  • •Organic sales growth decelerating and slowing (0.7% in Q1 to 1.6% in Q2 still modest), with volume decline in Q1
  • •Stock price stagnant (up only 0.3% post-Q2 earnings to $19.23) despite positive cash flow generation

Funds Buying (3)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Soros Fund ManagementSoros Family Office3.2M+1.9M$54M0.7%+153%Existing
Point72Steve Cohen461K+461K$8M<0.1%—NEW
Maverick CapitalLee Ainslie92K+92K$2M<0.1%—NEW

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.

Portfolio Context

Where KVUE ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.

Soros Fund Management

position #27 of this fund's book

  1. 24BERKSHIRE HATHAWAY INC DEL$64M
  2. 25WEC ENERGY GROUP INC$59M
  3. 26MEDLINE INC$57M
  4. 27KENVUE INC$54M
  5. 28COREBRIDGE FINL INC$51M
  6. 29BRIGHTHOUSE FINL INC$51M
  7. 30WEBSTER FINL CORP$49M

Values are quarter-end position sizes. Shown only for funds where KVUE ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.

Insider Activity

NameTitleTypeSharesPriceValueFiledSrc
Howlett HeatherCFO & CAOSELL4K$18.11$0.07M2026-06-10↗
Orlando MatthewGeneral CounselSELL38K$17.66$0.68M2026-05-08↗

Beneficial Ownership (13D/13G)

FilerFormShares% of ClassFiledSrc
T. Rowe Price Associates, Inc.SC 13G/A19.8M1.0%2026-02-17↗

SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.

Congressional Trading

MemberChamberStateTypeAmount RangeTransaction DateFiledSrc
Gilbert CisneroshouseCA31BUY$1,001 - $15,0002026-06-162026-07-02↗
Alan Armstrongsenate—BUY$1,001 - $15,0002026-03-272026-07-21↗
Earlier trades (1) — dated outside this quarter's window, not counted in the badges
MemberChamberStateTypeAmount RangeTransaction DateFiledSrc
Kevin HernhouseOK01SELL$1,001 - $15,0002026-08-052026-08-10↗

Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures. Members often file weeks or months after trading, so trades are placed by transaction date: the badges above count trades dated since Jan 1, 2026.